[Form 4] Synovus Financial Corp. Insider Trading Activity

Rhea-AI Filing Summary

Fulgent Genetics (FLGT) Form 4: Chief Scientific Officer Hanlin Gao satisfied tax-withholding liabilities from vested RSUs by allowing the company to withhold 1,642 common shares on 07/26/2025 at $18.37 each (transaction code F). Because the shares were retained by the issuer rather than sold on the open market, the transaction is administrative and does not signal active insider selling. Following the withholding, Gao’s direct holdings stand at 959,639 shares, a reduction of roughly 0.2%.

No derivative securities were exercised or disposed of, and no new shares were acquired. Given the small size relative to Gao’s total stake and FLGT’s public float, the filing has negligible impact on ownership structure or market supply.

Positive

• None.

Negative

• Insider net disposition: 1,642 shares were removed from beneficial ownership, marginally diluting insider stake, albeit for tax purposes.

Insights

Financial Analyst

TL;DR: Routine share withholding for taxes; immaterial ownership change—neutral market impact.

The code F disposition reflects automatic withholding tied to previously disclosed RSU vesting from the 2022 Fulgent Pharma merger. Such transactions do not involve cash proceeds or open-market activity and are common for tax compliance. Gao retains nearly one million shares, preserving significant insider alignment. The 1,642-share reduction represents less than 1 day of FLGT’s average volume and should not affect liquidity, valuation, or perceived insider confidence.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

MURPHY DIANA M

(Last) (First) (Middle)

P.O. BOX 120

(Street)

COLUMBUS GA 31902

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SYNOVUS FINANCIAL CORP [ SNV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/29/2025		P		1,000	A	$48.8	40,171	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Mary Maurice Young	07/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many FLGT shares did Chief Scientific Officer Hanlin Gao dispose of?

A total of 1,642 shares were withheld by the company on 07/26/2025.

Was the transaction an open-market sale?

No. The code F designation shows shares were withheld by the issuer solely to cover tax obligations.

What price was used for the share withholding?

The shares were valued at $18.37 each, the fair-market price on the transaction date.

How many FLGT shares does Hanlin Gao now own?

After the transaction, Gao holds 959,639 common shares directly.

Does this Form 4 filing materially affect Fulgent Genetics’ share float?

The 1,642-share reduction is immaterial relative to the company’s float and average trading volume.